Search

Displaying results 1431 - 1440 of 7536 in total
  1. Drug

    Vemurafenib

    go.drugbank.com/drugs/DB08881
    ApprovedInvestigational

    [A31269] It exerts its function by binding to the ATP-binding domain of the mutant BRAF. … [A31270] Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche.

  2. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    VIII, but does not contain the B-domain, which has no known biological function, and [DB13192], which is purified endogenous Factor VIII from human pooled blood and contains both A- and B-subunits. … To date, no confirmed inhibitory autoantibodies were seen in previously treated patients included in clinical studies and treatment-emergent adverse events were generally consistent with those expected

  3. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    It is used to treat elevated phosphate levels, primarily in patients with chronic kidney disease, by binding to dietary phosphate and preventing its absorption in the intestine.[L50733] … Lanthanum carbonate is a phosphate binder marketed under the trade name _Fosrenol_ by Shire Pharmaceuticals.

  4. Drug

    Insulin glulisine

    go.drugbank.com/drugs/DB01309
    Approved

    cells that the body is no longer able to produce insulin on its own. … Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able

  5. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.

  6. Drug

    Droperidol

    go.drugbank.com/drugs/DB00450
    ApprovedInvestigationalVet approved

    It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the … A butyrophenone with general properties similar to those of haloperidol.

  7. Drug

    Griseofulvin

    go.drugbank.com/drugs/DB00400
    ApprovedVet approved

    Griseofulvin may be given by mouth in the treatment of tinea infections.

  8. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264108, A264113, A264123] Deuruxolitinib works to block the inflammatory responses caused by JAKs.[L51068] … [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  9. Drug

    Eplerenone

    go.drugbank.com/drugs/DB00700
    ApprovedInvestigational

    The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. … Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

  10. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … Alpelisib was granted FDA approval on 24 May 2019.